Pro-Pharmaceuticals, Inc. Reports Preliminary Data Shows An Objective Partial Tumor Response In Phase II Colorectal Cancer Trial Evaluating DAVANAT(R) With 5-FU

NEWTON, Mass.--(BUSINESS WIRE)--April 5, 2006--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a developer of novel carbohydrate-based therapeutic compounds, today announced that preliminary data shows an objective partial tumor response from a patient in stage 1 of a Simon's 2-stage designed Phase II trial for third- and fourth-line treatment of colorectal cancer, according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. RECIST defines an objective response as a patient having a complete or partial response, with a partial response being at least a 50% reduction in total tumor size. Based on this preliminary data, the Company will not enroll patients in stage 2 and expects to begin dosing patients in a Europe-based Phase III trial for the second line treatment of colorectal cancer patients by the end of the second quarter of 2006.

Back to news